Quick Answer
Corbus Pharmaceuticals Holdings, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $0.00 for the year ending 2022.
- Corbus Pharmaceuticals Holdings, Inc. showed a decrease of -100.0% in Revenue From Contract With Customer Excluding Assessed Tax from 2021 to 2022.
- This data is from Corbus Pharmaceuticals Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 7, 2023.
- XBRL data for this metric is available from 2018 to 2022 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2018: $853.6 thousand | Q3 2018: $1.09 million | Q1 2019: $1.89 million | Q2 2019: $29.09 million | Q3 2019: $2.59 million | Q1 2020: $1.76 million | Q2 2020: $286.3 thousand | Q3 2020: $1.23 million | Q1 2021: $647.8 thousand | Q2 2021: $136.6 thousand | Q3 2021: $97.3 thousand | Q1 2022: $0.00 | Q3 2022: $0.00.
- Over the full 5 years of available data (2018 to 2022), Corbus Pharmaceuticals Holdings, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has declined by 100.0%.
- Historical annual values: Fiscal year 2022: $0.00 | Fiscal year 2021: $881.7 thousand | Fiscal year 2020: $3.94 million | Fiscal year 2019: $36.14 million | Fiscal year 2018: $4.82 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: